Regardless of the mechanism, the universal expression of BCL2A1 implies that this protein is necessary for survival in both ALK+ and ALK- ALCL, and therefore, it might be a potential candidate for targeted therapy. Here, ALK is linked to anaplastic large cell lymphoma.